Aktis Oncology, Inc. (AKTS)

Aktis Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-63.73	-43.98	-28.64	-17.93
Depreciation & Amortization	2.33	1.58	1.12	0.45
Stock-Based Compensation	5.13	2.26	1.48	0.7
Other Adjustments	-4.62	-4.07	-3.95	-0.2
Changes in Accounts Payable	-0.04	0.36	0.66	-0
Changes in Accrued Expenses	2.2	2.15	-0.23	2.54
Changes in Unearned Revenue	-5.5	58.51	-	-
Changes in Other Operating Activities	0.11	-2.05	-0.45	-3.68
Operating Cash Flow	-64.13	14.76	-30	-18.13
Capital Expenditures	-9.58	-2.86	-3.76	-2.31
Sale of Property, Plant & Equipment	-	-	0.06	-
Purchases of Investments	-193.87	-288.4	-145.81	-
Proceeds from Sale of Investments	269.42	100.86	80.69	-
Investing Cash Flow	65.96	-190.4	-68.83	-2.31
Issuance of Common Stock	0.34	0.18	-	-
Net Common Stock Issued (Repurchased)	0.34	0.18	-	-
Issuance of Preferred Stock	-	185	-	120.14
Net Preferred Stock Issued (Repurchased)	-	185	-	120.14
Other Financing Activities	-1.55	-1.9	-	-0.15
Financing Cash Flow	-1.21	183.28	-	119.98
Net Cash Flow	0.63	7.65	-98.83	99.55
Free Cash Flow	-73.71	11.9	-33.77	-20.43
FCF Margin	-1134.54%	800.27%	-	-
Free Cash Flow Per Share	-90.61	16.90	-54.89	-39.49
Levered Free Cash Flow	-74.22	13.71	-31.3	-20.93
Unlevered Free Cash Flow	-85.17	5.64	-37.45	-22.77

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q